# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
As part of the transaction, $8.1 million of the total consideration received from the sale of the PRV will be paid to Viracta T...
HC Wainwright & Co. analyst Andres Maldonado maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the...
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.72) per share which missed the analyst consensus estim...
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains...
Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and raises the price target from $30 ...
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rear...
JP Morgan analyst Anupam Rama maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price targe...